・Former Netflix CFO and Hims board member David Wells bought 48,400 shares worth about $1.17 million. ・Investor concerns intensified after Hims reported weak Q1 results that missed revenue and ...

Hims & Hers reversed course on its launch of a cheaper, copycat version of Novo Nordisk’s GLP-1 weight loss pill amid legal action. In a Feb. 7 social media post, the San Francisco-based telehealth ...

Last Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s ...

A pending FDA review of several peptides is giving investors a new growth story for Hims as the company resets its U.S. weight-loss business.

Hims & Hers faces a pivotal regulatory moment as the FDA reconsiders compounded peptide therapies, especially GLP-1 drugs like semaglutide. A permissive FDA framework could legitimize compounded ...

The telehealth company reported first-quarter 2026 revenue of $608.1 million, up 4% year over year, while subscribers continued growing across its weight-loss, sexual health, dermatology, and primary ...